Tag: Nellix

nellix

Endologix announces reinstatement of CE mark for its Nellix endovascular aneurysm...

Endologix recently announced that the EC Certificate of Conformity (CE mark) for the Nellix endovascular aneurysm sealing system (Nellix system) has been reinstated by...
nellix

EVAS2 IDE clinical study enrols first patient

The first patient has been treated in the EVAS2 IDE confirmatory clinical study of the investigational Nellix EndoVascular Aneurysm Sealing (EVAS) System (Endologix) by...
nellix

FDA grants IDE approval to Endologix for EVAS2 study of Nellix

Endologix has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to commence a confirmatory clinical study (EVAS2) to evaluate the...
nellix

Positive two-year Endologix Nellix clinical data presented at SVS 2017

Positive two-year clinical data from Endologix’ Nellix EVAS FORWARD investigative device exemption trial have been presented at the Society of Vascular Surgery (SVS; 31...

Personalising AAA Care With Polymer Sealing (OUS only)

In this supplement: -The clinical and biological advantages of active sac management with EVAS -10 things to know about Ovation -Ovation: Finally an endograft...

Endologix provides update on the Nellix sealing system US regulatory status

Endologix has met with the US Food and Drug Administration (FDA) regarding its Nellix endovascular aneurysm sealing system (EVAS System). Based upon that meeting and...

Andrew Holden: Nellix EVAS Global Forward Registry

  Andrew Holden (Auckland City Hospital, Auckland, New Zealand) is one of the principal investigators of the Nellix EVAS FORWARD Global Registry. He explained to...

Matt Thompson: The Endologix portfolio within the physician’s armamentarium

Matt Thompson (Chief Medical Officer, Endologix) speaks to Vascular News about what plans he has in his new role and the place of the...

Bob Mitchell: Latest developments in Nellix EVAS

  Speaking to Vascular News at the 2016 VEITHsymposium, Bob Mitchell (President, Endologix) discusses updated Nellix instructions for use and the potential of the endovascular...

Nellix IDE trial shows low morbidity and mortality with high procedural...

Primary safety and efficacy endpoints for the Nellix system (Endologix) investigational device exemption (IDE) trial have been achieved at one year, with “very low...